ArcelorMittal SA (ADR) (NYSE:MT) shares increased 1.54% in last trading session and ended the day at $4.61. MT has a return on assets of -9.90%. ArcelorMittal SA (ADR) (NYSE:MT) quarterly performance is 8.22%.
On 2 April, ArcelorMittal SA (ADR) (NYSE:MT) has idled the 84-inch hot strip mill at Indiana Harbor East Chicago as it looks to take capacity off-line in the United States at a time when only 71.6 percent of America’s steelmaking capacity is in use.
OXiGENE, Inc. (NASDAQ:OXGN) caters to the Healthcare space. Its weekly performance is -11.84%. On the last day of trading company shares ended up at $0.73. OXiGENE, Inc. (NASDAQ:OXGN) distance from 50-day simple moving average (SMA50) is 7.05%.
On 30 March, OXiGENE, Inc. (NASDAQ:OXGN) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CA4P for the treatment of platinum-resistant ovarian cancer. Companies with Fast Track designation are able to benefit from more frequent meetings and communications with the FDA regarding development plans to support product registration, and may also be eligible for priority review of New Drug Applications, which shortens FDA’s standard review timeline.
On 06 April, CME Group Inc. (NASDAQ:CME) shares fell -0.16% and was closed at $94.38. CME EPS growth in last 5 year was 5.20%. CME Group Inc. (NASDAQ:CME) year to date (YTD) performance is 4.84%.
CME Group Inc. (NASDAQ:CME) announced the appointment of Paul Houston as Executive Director, Global Head of FX. Reporting to Sean Tully, Senior Managing Director, Financial and OTC Products, CME Group, Houston will be responsible for leading the development, execution and management of the exchange’s FX business globally. He will be based in London.
Axovant Sciences Ltd. (NYSE:AXON) shares advanced 8.38% in last trading session and ended the day at $12.55. AXON has a return on assets of -47.50%. Axovant Sciences Ltd. (NYSE:AXON) quarterly performance is -22.29%.
Axovant Sciences Ltd. (NYSE:AXON) announced that the company will be presenting at the Goldman Sachs Alzheimer’s Symposium on April 11 at 11:25 a.m. EDT.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) caters to the Healthcare space. Its weekly performance is 9.70%. On the last day of trading company shares ended up at $9.78. Akebia Therapeutics, Inc. (NASDAQ:AKBA) distance from 50-day simple moving average (SMA50) is 12.32%.
Akebia Therapeutics Inc (NASDAQ:AKBA) had its price target lowered by investment analysts at HC Wainwright from $25.00 to $18.00 in a report released on Wednesday, StockTargetPrices.com reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s target price indicates a potential upside of 120.86% from the company’s previous close.
Leave a Reply